natgillin/translations-raw huggingface dataset:
Adverse reactions from clinical trials with Celvapan (H1N1)v in a healthy adult and older people are listed in the table below. 
Neželeni učinki, ki so jih ugotovili v kliničnih preskušanjih cepiva Celvapan (H1N1)v pri zdravih odraslih osebah in starostnikih, so navedeni v spodnji preglednici.
Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient. 
Pri bolnikih z endogeno ali jatrogeno zmanjšanim imunskim odzivom je protitelesni odziv
One pack of 20 multidose vials (type I glass) of 5 ml suspension (10 x 0.5 ml doses) with a stopper (bromobutyl rubber). 
Škatla s po 20 večodmernimi vialami (iz stekla vrste I) po 5 ml suspenzije (10 odmerkov po 0,5 ml)
Frequency 9 - 17 years 3 - 8 years 6 - 35 months 
3 - 8 let 6 - 35 mesecev
Caution is needed when administrating this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance(s), to any of the excipients and to trace residues e.g. formaldehyde, benzonase, or sucrose. 
Pri cepljenju oseb z znano preobčutljivostjo (poleg anafilaktične reakcije) na zdravilno učinkovino, katerokoli pomožno snov ali ostanke v sledeh, npr. formaldehid, benzonazo ali saharozo, je treba
Children and adolescents 3 to 17 years of age 
Otroci in mladostniki od 3 do 17 let starosti
Celvapan is a vaccine to prevent influenza (flu) caused by A(H1N1)v 2009 virus When a person is given the vaccine, the immune system (the body's natural defense system) will produce its own protection (antibodies) against the disease. 
Po cepljenju imunski sistem (naravni obrambni sistem telesa) ustvari lastno zaščito (protitelesa) proti bolezni.
Children and adolescents 6 months to 17 years of age In a clinical study the frequency and type of side effects after the first and second injection were basically similar to that seen in the adult and older population using Celvapan. 
V klinični študiji so bile pogostnosti in vrste neželenih učinkov po prvem in drugem odmerku cepiva v osnovi podobne kot pri odraslih in starostnikih, ki so prejeli cepivo Celvapan.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Celvapan suspension for injection 
IME ZDRAVILA IN POT(I) UPORABE
Uncommon: 
Izdelovalec:
See section 6.5 for the number of doses per vial. 
Število odmerkov na vialo je navedeno v poglavju 6.5.
If you get any of the side effects talk to your doctor. 
Če opazite katerikoli neželeni učinek, se posvetujte z zdravnikom.
Children and adolescents aged 6 months to 17 years of age: 
Otroci in mladostniki, stari od 6 mesecev do 17 let:
Immune response against a version of Celvapan containing A/H5N1 vaccine strains The immunogenicity of the vaccine containing 7.5 µg non-adjuvanted HA derived from strain A/Vietnam/1203/2004 has been evaluated in two clinical studies in adults aged 18 - 59 years (N = 312) and in older subjects aged 60 years and older (N = 272) following a 0, 21 day schedule. 
Imunogenost cepiva, ki vsebuje 7,5 µg HA brez adjuvansa, izdelanega s sevom A/Vietnam/1203/2004, je bila ocenjena v dveh kliničnih študijah pri odraslih, starih od 18 do 59 let (n=312), in pri starejših osebah, starih 60 let ali več (n=272), in sicer po shemi cepljenja na prvi in 21. dan.
In a clinical study the 7.5 µg dose of Celvapan (H1N1)v was administered to adults aged 18 to 59 years (N = 101) and older people over 60 years of age (N = 101). 
• Klinična preskušanja cepiva Celvapan (H1N1)v V klinični študiji so odmerek 7,5 µg cepiva Celvapan (H1N1)v dajali odraslim osebam, starim od 18 do 59 let (N= 101) in starostnikom, starejšim od 60 let (N=101).
In the clinical studies, most side effects were mild in nature and short term. 
V kliničnih študijah je bila večina neželenih učinkov
• you have had any allergic reaction other than a sudden life-threatening allergic reaction to any ingredient contained in the vaccine, to formaldehyde, benzonase, or to sucrose. 
• če ste imeli kdaj v preteklosti kakršnokoli drugo alergijsko reakcijo (poleg nenadne, življenjsko ogrožajoče alergijske reakcije) na katerokoli sestavino cepiva, formaldehid, Benzonazo ali saharozo (glejte poglavje 6.
The following adverse reactions were reported at a higher frequency category than in the 
Naslednji neželeni učinki so bili opaženi z večjo pogostnostjo kot v drugih kliničnih študijah:
This may include the provision by the MAH of stickers with invented name and batch number with each pack of the vaccine. 
V okviru teh ukrepov lahko imetnik dovoljenja za promet z zdravilom zagotovi nalepke z imenom cepiva in številko serije.
Persistence of anti-HA antibodies 180 days and 360 days after the first vaccination as measured by single radial hemolysis (SRH) and microneutralization assay (MN) in infants and young children aged 6 to 35 months was as follows: 
Perzistenca protiteles proti HA 180 dni in 360 dni po prvem odmerku cepiva, izmerjena z enkratno radialno hemolizo (SRH) in testom mikronevtralizacije (MN) po cepljenju dojenčkov in majhnih otrok, starih med 6 in 35 mesecev je bila naslednja:
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
If you get any side effects, talk to your doctor or nurse. 
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
• Injection site erythema 
• eritem na mestu injiciranja
None of the ingredients in the vaccine can 
Sestavine cepiva ne morejo povzročiti gripe.
Seronegative subjects at baseline (≤ 4mm 21 Days After nd 
Seronegativni preiskovanci v izhodišču (≤4 mm 21 dni po 1. odmerku 2. odmerku 1. odmerku 2. odmerku N=33
18 to 59 years 
9 - 17 let
The seroprotection rate, seroconversion rate and seroconversion factor for anti-HA antibody as measured by single radial haemolysis (SRH) in children aged 6 to 35 months were as follows: 
Odstotek serozaščite, odstotek serokonverzije in faktor serokonverzije, izmerjeni z enkratno radialno hemolizo (SRH) za protitelesa proti HA po cepljenju otrok, starih med 6 in 35 mesecev, so bili naslednji:
Persistence of anti-HA antibodies 180 days after the first vaccination as measured by single radial haemolysis (SRH) and microneutralisation assay (MN) in adults aged 18 to 59 years and in older subjects aged 60 years and above was as follows: 
Perzistenca protiteles proti HA 180 dni po prvem odmerku cepiva, izmerjena z enkratno radialno hemolizo (SRH, single radial haemolysis) in testom mikronevtralizacije (MN) po cepljenju odraslih, starih med 18 in 59 let, ter starejših oseb, starih 60 let in več, so bili naslednji:
* SRH area > 25 mm² ** either SRH area > 25 mm² if baseline sample negative or 50% increase in SRH area if baseline sample > 4 mm² *** geometric mean increase 
* površina SRH >25 mm² ** bodisi površina SRH > 25 mm² (če je osnovni vzorec negativen) bodisi 50-odstotno povečanje površine SRH, če je začetni vzorec >4 mm² *** geometrična sredina povečanja
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL FOR 10-DOSE VIAL 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (e.g. formaldehyde, benzonase, sucrose) of this vaccine. 
Anafilaktična reakcija v anamnezi (npr. življenjsko nevarna) zaradi preobčutljivosti na katerokoli sestavino cepiva ali ostanke v sledeh (npr. formaldehid, benzonaza, saharoza).
6.6 Special precautions for disposal and other handling 
6.4 Posebna navodila za shranjevanje
In a clinical trial 51 children and adolescents aged 9 to 17 years and 51 children aged 3 to 8 years were administered the 7.5 µg dose of Celvapan (H1N1)v. The incidence and nature of symptoms after the first and second vaccination were similar to that observed in the adult and older population using 
V kliničnem preskušanju so 51 otrokom in mladostnikom, starim od 9 do 17 let, ter 51 otrokom, starim od 3 do 8 let, dali odmerek cepiva Celvapan (H1N1)v 7,5 µg.
After vaccination the rate of subjects with neutralizing antibody titres ≥ 40, seroconversion rate and seroconversion factor as measured by microneutralisation assay (MN) in children and adolescents aged 3 to 17 years were as follows: 
Odstotek oseb, ki imajo titer nevtralizirajočih protiteles ≥ 40, ter odstotek serokonverzije in faktor serokonverzije, izmerjeni s testom mikronevtralizacije (MN) po cepljenju otrok in mladostnikov, starih od 3 do 17 let, so bili naslednji:
After vaccination the seroprotection rate, seroconversion rate and seroconversion factor for anti-HA antibody as measured by single radial haemolysis (SRH) in adults aged 18 to 59 years and in older subjects aged 60 years and above were as follows: 
Odstotek serozaščite, odstotek serokonverzije in faktor serokonverzije, izmerjeni z enkratno radialno hemolizo (SRH, single radial haemolysis) za protitelesa proti HA po cepljenju odraslih, starih med 18 in 59 let, ter starejših oseb, starih 60 let in več, so bili naslednji:
The seroprotection rate, seroconversion rate and seroconversion factor for anti-HA antibody as measured by single radial haemolysis (SRH) in children and adolescents aged 3 to 17 years were as 
Odstotek serozaščite, odstotek serokonverzije in faktor serokonverzije, izmerjeni z enkratno radialno hemolizo (SRH) za protitelesa proti HA po cepljenju otrok in mladostnikov, starih med 3 in 17 let, so
Very common: Injection site redness, drowsiness, irritability, loss of appetite, crying 
Otroci, stari od 6 mesecev do 5 let: Zelo pogosti: pordelost na mestu injiciranja, zaspanost, razdražljivost, zmanjšan apetit, jok
After vaccination the rate of subjects with neutralizing antibody titres ≥ 40, seroconversion rate and seroconversion factor as measured by microneutralisation assay (MN) in adults aged 18 to 59 years and in older subjects aged 60 years and above were as follows: 
Odstotek oseb, ki imajo titer nevtralizirajočih protiteles ≥ 40, ter odstotek serokonverzije in faktor serokonverzije, izmerjeni s testom mikronevtralizacije (MN) po cepljenju odraslih, starih od 18 do 59 let, in starostnikov, starih 60 let ali več, so bili naslednji:
Antibody persistence 
Perzistenca protiteles
• Injection site induration 
• zatrdlina na mestu injiciranja
INFECTIONS AND INFESTATIONS Nasopharyngitis 
INFEKCIJSKE IN PARAZITSKE BOLEZNI
Celvapan may be used in lactating women. 
Cepivo Celvapan se lahko uporablja tudi pri doječih materah.
Seroprotection / Seroneutralization rate* 
Odstotek serozaščite /
Persistence of anti-HA antibodies 180 days and 360 days after the first vaccination as measured by single radial hemolysis (SRH) and microneutralization (MN) assay in children and adolescents 
Perzistenca protiteles proti HA 180 dni in 360 dni po prvem odmerku cepiva, izmerjena z enkratno radialno hemolizo (SRH) in testom mikronevtralizacije (MN) po cepljenju otrok in mladostnikov, starih med 3 in 17 let je bila naslednja:
Pharyngolaryngeal pain 
nazofaringitis pogosti
• Injection site pain 
• bolečine na mestu injiciranja
The following information is intended for medical or health care professionals only: Prior to administration, the vaccine should be allowed to reach room temperature and the vial should 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Pred cepljenjem počakajte, da cepivo doseže sobno temperaturo.
Seronegative subjects at baseline 21 Days After nd 
Seronegativni preiskovanci v izhodišču (<1:10) 21 dni po 1. odmerku
** either SRH area > 25 mm² if baseline sample negative or 50% increase in SRH area if baseline sample > 4 mm²; > 4-fold increase in MN titer; 
** bodisi površina SRH > 25 mm² (če je osnovni vzorec negativen) bodisi 50-odstotno povečanje površine SRH, če je začetni vzorec >4 mm²; >4-kratno povečanje titra MN;
Pain in extremity (in the majority of cases reported as pain in the injection site arm) General disorders and administration site conditions: 
Bolezni mišično-skeletnega sistema in vezivnega tkiva Bolečine v udu (v večini zabeleženih primerov bolečina v roki, v katero je bilo vneseno cepivo)
• Pain, redness, swelling or a hard lump where the injection was given, reduced movement in the Side effects from clinical studies in children 
• zvišana telesna temperatura, mrzlica, slabo počutje, • bolečine, rdečina, oteklina ali zatrdlina na mestu injiciranja, zmanjšana gibljivost roke, v katero
The following additional adverse reactions have been reported in the post-marketing experience in adults and children receiving Celvapan (H1N1)v. 
Izkušnje v obdobju trženja pri odraslih osebah in otrocih, ki so prejeli cepivo Celvapan (H1N1)v so pokazale naslednje dodatne neželene učinke.
The side effects listed below have occurred with Celvapan (H1N1)v in adults and children during the 
Spodaj navedeni neželeni učinki so se pojavljali pri uporabi cepiva Celvapan (H1N1)v pri odraslih osebah in otrocih v programu cepljenja proti pandemski gripi.
After vaccination the rate of subjects with neutralizing antibody titres ≥ 40, seroconversion rate and seroconversion factor as measured by microneutralisation assay (MN) in children aged 6 to 35 months 
Odstotek oseb, ki imajo titer nevtralizirajočih protiteles ≥ 40, ter odstotek serokonverzije in faktor serokonverzije, izmerjeni s testom mikronevtralizacije (MN) po cepljenju otrok in mladostnikov, starih od 6 do 35 mesecev, so bili naslednji:
** either SRH area > 25 mm² if baseline sample negative or 50% increase in SRH area if baseline 
** bodisi površina SRH > 25 mm² (če je osnovni vzorec negativen) bodisi 50-odstotno povečanje površine SRH, če je začetni vzorec >4 mm²
See section 4. 
Navodilo shranite.
There are no data with Celvapan using the subcutaneous route. 
Ni podatkov o subkutanem injiciranju cepiva Celvapan.
** either SRH area > 25 mm² if baseline sample negative or 50% increase in SRH area if baseline sample > 4 mm²; > 4-fold increase in MN titre; 
** bodisi površina SRH > 25 mm² (če je osnovni vzorec negativen) bodisi 50-odstotno povečanje površine SRH, če je začetni vzorec >4 mm²; >4-kratno povečanje titra MN; *** geometrična sredina povečanja
<Content (concentration)> 
<Vsebina (koncentracija)>
(Invented) name Strength Pharmaceutical form 
(Izmišljeno) ime Jakost Farmacevtska oblika
<EMA procedure number> <MA (EU) number> 
<Številka postopka EMA> <Številka (EU) dovoljenja za promet>
powder: 90 mg; solvent: 2 ml 
prašek: 90 mg; vehikel: 2 ml
60 vials powder + 60 vials solvent + 60 3 ml syringes + 60 1 ml syringes + 180 alcohol swabs 
60 vial praška + 60 vial vehikla + 60 3-ml injekcijskih brizg + 60 1-ml injekcijskih brizg +
Subcutaneous use powder: vial (glass); solvent: vial (glass) 
Fuzeon mg/ml prašek in vehikel za raztopino za injiciranje subkutana uporaba prašek: viala (steklo); vehikel: viala (steklo)
Pack size 
alkoholnih blazinic
Open the bottle. 
Odprite stekleničko.
These effects should however decrease over time. 
Vendar se ti učinki sčasoma zmanjšajo.
The mechanism of this risk is not known. 
Mehanizem tega tveganja ni znan.
Food and alcohol 
Hrana in alkohol
Date of first authorisation: 5 December 2011 Date of latest renewal: 08 August 2016 
Datum prve odobritve: 5. december 2011 Datum zadnjega podaljšanja: 8. avgust 2016
After first opening: 7 months 
3 leta Po prvem odprtju: 7 mesecev
Age also had an influence on both parameters. 
Na oba parametra je vplivala tudi starost.
In the elderly, the half-life is increased by about 40% (10 to 11 hours). 
Pri starejših se razpolovni čas podaljša za približno 40 % (10 do 11 ur).
The elimination half-life was approximately 5 hours. 
Eliminacijski razpolovni čas je bil približno 5 ur.
This leaflet was last revised in {month/YYYY}. 
Navodilo je bilo nazadnje revidirano {mesec/LLLL}.
Duration of treatment: 
Trajanje zdravljenja:
No clinical data are available, potential risk for human is unknown. 
Kliničnih podatkov ni in potencialno tveganje za človeka ni znano.
Tell your doctor immediately, or go to your nearest emergency department, if you experience: 
Takoj obvestite zdravnika ali pojdite do najbližje urgence, če opazite:
In such case, the lowest effective dose is recommended. 
V tem primeru se priporoča najmanjši učinkovit odmerek.
This decrease is more pronounced during the third trimester (up to 60 % of baseline concentration before pregnancy). 
To znižanje je izrazitejše v tretjem trimesečju (do 60 % izhodiščne koncentracije pred nosečnostjo).
BG-5600 Troyan Bulgaria 
BG-5600 Troyan Bolgarija
These could be symptoms of an encephalopathy. 
To so lahko znaki encefalopatije.
• encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of symptoms); 
• encefalopatija (glejte podpoglavje »Takoj obvestite zdravnika« za podroben opis simptomov)
This is more likely at the beginning of treatment or after an increase in the dose. 
To je verjetneje na začetku zdravljenja in po povečanju odmerka.
However, current epidemiological studies (on about 100 children) do not suggest an increased risk of neurodevelopmental disorders or delays. 
Vendar pa trenutne epidemiološke študije (pri približno 100 otrocih) ne kažejo na povečano tveganje za nevrološko razvojne motnje ali zaostalosti.
Available data in children did not suggest impact on growth and puberty. 
Podatki, ki so na voljo za otroke, ne kažejo vpliva na rast in puberteto.
This is related to the decrease in renal function in this population (see section 4.2). 
To je povezano z zmanjšanim delovanjem ledvic v tej populaciji (glejte poglavje 4.2).
The lowest effective dose should be used. 
Uporabiti je treba najmanjši učinkoviti odmerek.
No impact on fertility was detected in animal studies (see section 5.3). 
V študijah na živalih niso ugotovili vpliva na plodnost (glejte poglavje 5.3).
Patients with rare hereditary problems of fructose intolerance should not take this medicine. 
Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati tega zdravila.
* Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients. 
*Prevalenca je bistveno višja pri japonskih bolnikih v primerjavi z ne-japonskimi bolniki.
Appropriate clinical management of pregnant women treated with levetiracetam should be ensured. 
Zagotoviti je treba ustrezno klinično vodenje nosečnic, zdravljenih z levetiracetamom.
Suicide 
Samomor
The mechanism of action of levetiracetam still remains to be fully elucidated. 
Mehanizem delovanja Mehanizem delovanja levetiracetama še ni povsem pojasnjen.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati.
Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. 
Hidroliza acetamidne skupine je merljiva v številnih tkivih, tudi v krvnih celicah.
However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown. 
Vendar dolgoročni vplivi na učenje, inteligenco, rast, endokrino delovanje, puberteto in zmožnost imeti otroke pri otrocih ostajajo neznani.
No data are available. 
Na razpolago ni nobenih podatkov..
There is no evidence for any relevant gender, race or circadian variability. 
Ni znakov pomembne variabilnosti med spoloma, med rasami ali cirkadiano.
The major metabolic pathway (24% of the dose) is an enzymatic hydrolysis of the acetamide group. 
Glavna presnovna pot (24 % odmerka) je encimska hidroliza acetamidne skupine.
There was no effect on embryomortality and no increased incidence of malformations. 
Vpliva na umrljivost zarodkov ni bilo, prav tako se ni povečala incidenca malformacij.
However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding. 
Če pa je zdravljenje z levetiracetamom med obdobjem dojenja potrebno, je treba koristi in tveganja takšnega zdravljenja pretehtati upoštevaje pomen dojenja.
The results are consistent across age group. 
Rezultati po starostnih skupinah se skladajo.
The metabolite ucb L057 is pharmacologically inactive. 
Presnovek ucb L057 je farmakološko neaktiven.
• If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6). 
• Če ste alergični na levetiracetam, pirolidonske derivate ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
as an add-on to other antiepileptic medicines to treat: 
• kot dodatek drugim antiepileptičnim zdravilom za zdravljenje:
• severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], 
• hude alergijske reakcije (DRESS, anafilaktična reakcija [huda in pomembna alergijska reakcija],
Be sure to drink the whole contents of the glass. 
Poskrbite, da boste popili celotno vsebino kozarca.
Your doctor will establish the best possible treatment of overdose. 
Zdravnik bo določil najustreznejše zdravljenje prevelikega odmerjanja.
Therefore, the interaction of levetiracetam with other substances, or vice versa, is unlikely. 
Zato medsebojno delovanje levetiracetama drugimi snovmi ali drugih snovi z njim ni verjetno.
Do not use this medicine after the expiry date which is stated on the cardboard box and bottle after EXP:. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na kartonski škatli in na steklenički poleg oznake EXP.
CLcr (ml/min) = ----------------------------------------- (x 0.85 for women) 
CLcr (ml/min) = ----------------------------------------- (x 0,85 za ženske)
Nervous system Somnolence, 
Bolezni živčevja somnolenca,
Read all of this leaflet carefully before you or your child start taking this medicine because it contains important information for you. 
Pred začetkom jemanja zdravila vi ali vaš otrok natančno preberite navodilo, ker vsebuje za vaju pomembne podatke!
No data on the interaction of levetiracetam with alcohol are available. 
Podatkov o interakciji levetiracetama z alkoholom ni.
Physiological changes during pregnancy may affect levetiracetam concentration. 
Fiziološke spremembe lahko med nosečnostjo vplivajo na koncentracijo levetiracetama.
For adult patients, refer to the following table and adjust the dose as indicated. 
Za odrasle bolnike glejte naslednjo preglednico in prilagodite odmerek, kot je označeno.
This effect was pronounced for the younger infants, and subsided as age increased, to become negligible around 4 years of age. 
Ta učinek je bil izrazit pri mladih dojenčkih in se je s povečevanjem starosti manjšal, tako da je okrog 4. leta postal zanemarljiv.
• decreased number of blood platelets, decreased number of white blood cells; 
• zmanjšano število krvnih ploščic, zmanjšano število belih krvnih celic
Other unidentified components accounted only for 0.6% of the dose. 
Na račun drugih, neidentificiranih sestavin gre le 0,6 % odmerka.
Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected. 
Bolnikom je treba naročiti, naj ne vozijo in ne uporabljajo strojev, dokler se ne izkaže, da njihova sposobnost za opravljanje takšnih dejavnosti ni prizadeta.
Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may result in a reduction of its effect. 
Ne jemljite makrogola (učinkovina, ki se uporablja kot laksativ) eno uro pred in eno uro po jemanju levetiracetama, ker lahko zmanjša učinek levetiracetama.
72 x serum creatinine (mg/dl) 
72 x kreatinin v serumu (mg/dl)
Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients. 
Pogostnost je bistveno višja pri japonskih bolnikih v primerjavi z ne-japonskimi bolniki.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Če ste noseči ali dojite, mislite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14 
Farmakoterapevtska skupina: antiepileptiki, drugi antiepileptiki, oznaka ATC: N03AX14
[140-age (years)] x weight (kg) 
[140-starost (let)] x masa (kg)